comprehensive -WSS

comprehensive

author：comprehensive 2025-09-28 01:35:32 - browse：839

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

leisure time

WSS

Feng Zhang, Grail founder join forces on new gene editing startup

GSK Flovent asthma inhalers replaced by authorized generics

New Medicare drug pricing powers could soon be upended in court

Antibiotic resistance and the global rise in human conflict

How a scoliosis diagnosis changed the life of one young dancer

New menopause drug shows promise in relief for hot flashes

knowledge

comprehensive

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Morgan Health, with ambitious aims, wants you to know it’s still here

Walensky prepares to leave CDC — and Congress — behind

DeSantis can now import cheaper drugs. But will Biden get credit?

In Memoriam: Notable people who died in 2023

Why psychiatrists like me stop taking insurance

The cancer drug shortage isn’t new — and neither are the solutions

New weight loss drugs work. But how can they best be used?

How one medical school became remarkably diverse

Goldman Sachs launches $650M fund for life science investments

entertainment

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

A single drug, study failures leave Anavex with nothing but cash

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Ahead of JPM, here's who's profiting most in health care

leisure time

leisure time

hotspot

focus